Christiane Falge

Nuernberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Journal: Haematologica
Published: September 23, 2018

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Journal: Leukemia
Published: November 08, 2017

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Journal: Leukemia
Published: June 23, 2017

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

Journal: Annals of hematology
Published: June 15, 2015

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Journal: Leukemia
Published: March 25, 2015

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Journal: Leukemia
Published: September 23, 2014

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Journal: Haematologica
Published: May 20, 2014

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.

Journal: Journal of cancer research and clinical oncology
Published: March 19, 2014

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Journal: Leukemia
Published: March 06, 2014

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 04, 2013

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Journal: Annals of hematology
Published: July 25, 2013

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Journal: Leukemia
Published: March 27, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026